·The first new-generation recombinant human coagulation factor VIII derived from a humanized cell line ·Benefiting 140,000 haemophilia patients ·The only new-generation recombinant Factor VIII (rFVIII) in China derived from a humanized cell line ·Both the preparation process and formulation are new patents

*For contraindications and adverse reactions, please see the package insert

·The world's first CD20 monoclonal antibody ·Authoritative guidelines such as NCCN and CSCO recommend R-based regimens (treatment regimens based on Rituximab) as the first choice for the treatment of lymphomas such as DLBCL, FL, MZL, MCL, and CLL/SLL ·Strictly follows biosimilar development standards

*For contraindications and adverse reactions, please see the package insert

·Used in combination with Trastuzumab for the treatment of HER2-positive early breast cancer and metastatic breast cancer ·Pertuzumab is recommended by multiple authoritative domestic and international guidelines (NCCN, CSCO, CACA, etc.). The dual-target combination therapy with Trastuzumab is the current standard of care for perioperative treatment of HER2-positive early breast cancer and first-line treatment of advanced breast cancer

*For contraindications and adverse reactions, please see the package insert

·Category 1 new drug ·The world's first 99.9% pure trans-isomer glycyrrhizinate ·Winner of the "China Patent Gold Award" ·The first and only drug in China approved for the indication of acute drug-induced liver injury ·Served over 35 million patients cumulatively

*For contraindications and adverse reactions, please see the package insert

·First domestically produced cataplasm ·Leading brand in topical analgesics for many consecutive years, used for various types of inflammatory pain ·Recommended by 15 authoritative guidelines, including the "Guidelines for the Diagnosis and Treatment of Osteoarthritis" and the "Chinese Expert Consensus on the Management of Chronic Musculoskeletal Pain in the Elderly", and included in the "Guidelines for the Use of Commonly Used Therapeutic Drugs for Athletes (2020 Edition)" ·Selected as a national "Patent-Intensive Product" ·Served over 100 million patients cumulatively

*For contraindications and adverse reactions, please see the package insert

·The first small-molecule chemical drug in China for the treatment of lumbar spinal stenosis ·Improves neural microcirculation through a dual mechanism, breaking the technological bottleneck of ineffective oral administration of prostaglandin drugs ·Supported by the Industrial Strong Foundation Project of the Ministry of Industry and Information Technology

*For contraindications and adverse reactions, please see the package insert

·A glucagon-like peptide-1 (GLP-1) receptor agonist with evidence of both cardiovascular and renal benefits ·Recommended as a first-line treatment in the "2024 China Diabetes Prevention and Treatment Guidelines" for patients with type 2 diabetes mellitus who are overweight or have obesity, with established atherosclerotic cardiovascular disease (ASCVD) or high risk, or with chronic kidney disease (CKD)

*For contraindications and adverse reactions, please see the package insert

·A fully human monoclonal antibody that targets and inhibits tumour necrosis factor-alpha ·Approved for multiple indications, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease ·Multiple clinical trials have shown that Adalimumab can effectively alleviate disease activity, improve joint function and skin lesion symptoms, and achieve long-term disease control in some patients ·Pre-filled syringe design simplifies operation and improves medication adherence

*For contraindications and adverse reactions, please see the package insert